Angiomotin

Last updated
AMOT
Identifiers
Aliases AMOT , angiomotin
External IDs OMIM: 300410 MGI: 108440 HomoloGene: 15778 GeneCards: AMOT
Orthologs
SpeciesHumanMouse
Entrez
Ensembl
UniProt
RefSeq (mRNA)

NM_001113490
NM_133265
NM_001386998
NM_001386999

NM_001290274
NM_153319

RefSeq (protein)

NP_001106962
NP_573572

Location (UCSC)n/a Chr X: 144.23 – 144.29 Mb
PubMed search [2] [3]
Wikidata
View/Edit Human View/Edit Mouse

Angiomotin (AMOT) is a protein that in humans is encoded by the AMOT gene. [4] [5] [6] [7] It belongs to the motin family of angiostatin binding proteins, which includes angiomotin, angiomotin-like 1 (AMOTL1) and angiomotin-like 2 (AMOTL2) characterized by coiled-coil domains at N-terminus and consensus PDZ-binding domain at the C-terminus. [6] Angiomotin is expressed predominantly in endothelial cells of capillaries as well as angiogenic tissues such as placenta and solid tumor. [8]

Contents

Discovery

Angiomotin was discovered in 2001 by screening a placenta yeast two-hybrid cDNA library for angiostatin-binding peptides, using a construct encoding the kringle domains 1-4 of angiostatin. [4]

Gene location

AMOT gene is located on human chromosome X:112,021,794-112,066,354, containing 3252 nucleotides in coding sequence as 11 exons. [9]

Protein structure

Two splice isoforms are known for angiomotin: p80 and p130. The alternative splicing is somewhat tissue specific. Cells expressing p130 contained more actin than those expressing p80. p80 is not the product of cleavage of p130, as p130 contains no potential proteolytic cleavage site for such conversion. [10]

Angiomotin p80 is a 72.54 kD protein of 675 residues, [11] characterized by conserved N-terminal coiled coil domains and C-terminal PDZ binding motifs, with angiostatin binding domain (ABD) located in the central region. It is hypothesized that the ABD is extracellular, while the coiled-coil and the PDZ binding domain are intracellular. [5] The PDZ-binding motif of angiomotin serves as a protein recognition site and deletion of as few as three amino acids from the C-terminal results in complete loss of pro-migratory activity, and endothelial cells expressing such mutant angiomotin failed to migrate or form tubes. [12]

Angiomotin p130 differs from p80 by having an N-terminal cytoplasmic extension of 409 amino acids rich in glutamine, which mediates the binding of p130 to F-actin and tight cell-cell junctions. This binding remains after destabilizing actin with cytochalasin B. [10]

Like other surface-associated proteins that can bind plasminogen and its derivatives, angiomotin does not appear to have a signal sequence, thus its association with the cell surface may be via protein–protein interaction usually referred to as non-classic secretion. [8]

Function

Role in cell motility and angiogenesis

Expression of angiomotin p80 in endothelial cells increases the random migration of endothelial cells, as well as the migration of endothelial cells toward growth factors, e.g. bFGF, VEGF and LPA etc. Angiomotin also mediates tube formation of endothelial cells. [4] [12] Angiomotin promotes angiogenesis by both stimulating cell spreading and stabilizing established tubes, e.g. in mouse aortic endothelial (MAE) cells the tubes remained stable for over 30 days, while control tubes started to regress after 3 days. [13] In the presence of angiostatin, endothelial cells expressing angiomotin p80 exhibit reduction in migration as well as reduction in tubules formation in vitro. These observations are consistent with the localization of angiomotin in the leading edge of migrating cells. Angiostatin therefore, is an inhibitor of angiomotin.

Angiomotin p80 locates and binds angiostatin on the cell surface. In primary endothelial of Chinese hamster ovary, it localizes to cell-cell junction, recruits ZO-1 and interacts with MAGI-1. It may play a role in the assembly of endothelial cell-cell junctions, as well. [5]

Angiomotin p130 does not promote cell migration, nor responds to angiostatin. It localizes to cell-cell junction like p80 and regulates paracellular permeability. Its N-terminal domain localizes to actin fibers and stabilizes them, and this effect is not affected by angiostatin. Transfection of p130 angiomotin into MAE cells results in change in cell shape, increased average cell size and stress fiber formation. So p80 is involved in cell migration and expressed during migratory phase. While p130 controls cell shape by interaction with actin, and is expressed during the period of blood vessel stabilization and maturation. [10] [14] The relative expression levels of p80 and p130 regulate a switch between a migratory and a non-migratory cell phenotype, where homo-oligomerization of p80 and hetero-oligomerization of both isoforms are critical for this regulation. [14]

Role in Hippo signaling pathway

AMOT, AMOTL1 and AMOTL2 play critical roles in the Hippo signaling pathway by regulating the subcellular localization of the co-activators YAP (Yes-associated protein) and TAZ (transcriptional co-activator with PDZ-binding motif), [15] and activating LATS2 through a novel conserved domain. [16] The activity of YAP and TAZ can be restricted through their interaction with AMOT and AMOTL1, and such interaction depends on the WW domain of TAZ and the Proline-Proline-x–Tyrosine motif at the N-terminus of AMOT. [17]

In position-dependent Hippo signaling, where the outer and inner cells are polar and nonpolar respectively, AMOT and AMOTL2 are essential for Hippo pathway activation and appropriate cell fate specification. In the nonpolar inner cells, AMOT localizes to adherens junctions (AJs), and Ser-176 at the N-terminal domain is phosphorylated by LATS downstream of GPCR signaling, which inhibits actin binding activity and stabilizes the AMOT-LATS interaction to activate the Hippo pathway. Thus, AMOT is a direct substrate of LATS and its phosphorylation at Ser-176 inhibits cell migration and angiogenesis. In the outer cells, the cell polarity sequesters AMOT from basolateral adherens junctions to apical domains, thereby suppressing Hippo signaling. [18] [19] It is therefore proposed AMOT acts as a molecular switch for Hippo pathway and links F-actin with LATS activity. [20]

Along the Hippo pathway, AMOT's binding to Merlin releases its auto-inhibition and promotes Merlin's binding to LATS1/2. Phosphorylation of Ser-518 outside the Merlin's auto-inhibitory tail prevents binding and thus inhibits Hippo pathway kinase activation. [21] USP9x regulates the ubiquitin-mediated turnover of AMOT, and the deubiquitylation of AMOT results in its stabilization and lower YAP/TAZ activity. [22]

Cancer research

A DNA vaccination targeting angiomotin generated antibodies that detected AMOT on the endothelial cell surface, which inhibited migration. It blocked angiogenesis and prevented growth of transplanted tumors for up to 150 days in vivo. A combination of DNA vaccines encoding AMOT and the extracellular and transmembrane domains of the human EGF receptor 2 (Her-2)/neu oncogene inhibited breast cancer progression and impaired tumor vascularization in Her-2/neu transgenic mice, showing DNA vaccination targeting AMOT may be used to mimic the effect of angiostatin and no toxicity or impairment of normal blood vessels was detected. [23]

In human breast cancer tissues, AMOT is highly expressed compared with control, and its level is associated with other angiogenesis markers. AMOT links to the proliferation and invasion of breast tumours and the long-term survival of the patients, and could be a potential target for therapy. [24] [25]

For melanoma, AMOT binds a variant of soluble cell adhesion molecule (sCD146) in endothelial progenitor cells (EPC). Silencing AMOT in EPC inhibits the angiogenic effect of sCD146, e.g. EPC migration, proliferation, and capacity to form capillary-like structures in Matrigel. [26]

Related Research Articles

Angiostatin is a naturally occurring protein found in several animal species, including humans. It is an endogenous angiogenesis inhibitor. Clinical trials have been undertaken for its use in anticancer therapy.

<span class="mw-page-title-main">Angiogenin</span> Protein-coding gene in the species Homo sapiens

Angiogenin (ANG) also known as ribonuclease 5 is a small 123 amino acid protein that in humans is encoded by the ANG gene. Angiogenin is a potent stimulator of new blood vessels through the process of angiogenesis. Ang hydrolyzes cellular RNA, resulting in modulated levels of protein synthesis and interacts with DNA causing a promoter-like increase in the expression of rRNA. Ang is associated with cancer and neurological disease through angiogenesis and through activating gene expression that suppresses apoptosis.

<span class="mw-page-title-main">Endoglin</span> Protein-coding gene in the species Homo sapiens

Endoglin (ENG) is a type I membrane glycoprotein located on cell surfaces and is part of the TGF beta receptor complex. It is also commonly referred to as CD105, END, FLJ41744, HHT1, ORW and ORW1. It has a crucial role in angiogenesis, therefore, making it an important protein for tumor growth, survival and metastasis of cancer cells to other locations in the body.

<span class="mw-page-title-main">Ephrin</span>

Ephrins are a family of proteins that serve as the ligands of the Eph receptor. Eph receptors in turn compose the largest known subfamily of receptor protein-tyrosine kinases (RTKs).

<span class="mw-page-title-main">CDC42</span> Protein-coding gene in the species Homo sapiens

Cell division control protein 42 homolog is a protein that in humans is encoded by the CDC42 gene. Cdc42 is involved in regulation of the cell cycle. It was originally identified in S. cerevisiae (yeast) as a mediator of cell division, and is now known to influence a variety of signaling events and cellular processes in a variety of organisms from yeast to mammals.

<span class="mw-page-title-main">Transforming protein RhoA</span> Protein and coding gene in humans

Transforming protein RhoA, also known as Ras homolog family member A (RhoA), is a small GTPase protein in the Rho family of GTPases that in humans is encoded by the RHOA gene. While the effects of RhoA activity are not all well known, it is primarily associated with cytoskeleton regulation, mostly actin stress fibers formation and actomyosin contractility. It acts upon several effectors. Among them, ROCK1 and DIAPH1 are the best described. RhoA, and the other Rho GTPases, are part of a larger family of related proteins known as the Ras superfamily, a family of proteins involved in the regulation and timing of cell division. RhoA is one of the oldest Rho GTPases, with homologues present in the genomes since 1.5 billion years. As a consequence, RhoA is somehow involved in many cellular processes which emerged throughout evolution. RhoA specifically is regarded as a prominent regulatory factor in other functions such as the regulation of cytoskeletal dynamics, transcription, cell cycle progression and cell transformation.

<span class="mw-page-title-main">ROCK1</span> Protein

ROCK1 is a protein serine/threonine kinase also known as rho-associated, coiled-coil-containing protein kinase 1. Other common names are ROKβ and P160ROCK. ROCK1 is a major downstream effector of the small GTPase RhoA and is a regulator of the actomyosin cytoskeleton which promotes contractile force generation. ROCK1 plays a role in cancer and in particular cell motility, metastasis, and angiogenesis.

<span class="mw-page-title-main">Brain-specific angiogenesis inhibitor 1</span> Protein-coding gene in the species Homo sapiens

Brain-specific angiogenesis inhibitor 1 is a protein that in humans is encoded by the BAI1 gene. It is a member of the adhesion-GPCR family of receptors.

<span class="mw-page-title-main">PEDF</span> Protein-coding gene in the species Homo sapiens

Pigment epithelium-derived factor (PEDF) also known as serpin F1 (SERPINF1), is a multifunctional secreted protein that has anti-angiogenic, anti-tumorigenic, and neurotrophic functions. Found in vertebrates, this 50 kDa protein is being researched as a therapeutic candidate for treatment of such conditions as choroidal neovascularization, heart disease, and cancer. In humans, pigment epithelium-derived factor is encoded by the SERPINF1 gene.

<span class="mw-page-title-main">YAP1</span> Protein-coding gene in the species Homo sapiens

YAP1, also known as YAP or YAP65, is a protein that acts as a transcription coregulator that promotes transcription of genes involved in cellular proliferation and suppressing apoptotic genes. YAP1 is a component in the hippo signaling pathway which regulates organ size, regeneration, and tumorigenesis. YAP1 was first identified by virtue of its ability to associate with the SH3 domain of Yes and Src protein tyrosine kinases. YAP1 is a potent oncogene, which is amplified in various human cancers.

<span class="mw-page-title-main">RhoG</span> Protein-coding gene in the species Homo sapiens

RhoG is a small monomeric GTP-binding protein, and is an important component of many intracellular signalling pathways. It is a member of the Rac subfamily of the Rho family of small G proteins and is encoded by the gene RHOG.

<span class="mw-page-title-main">MAGI1</span> Protein-coding gene in the species Homo sapiens

Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 1 is an enzyme that in humans is encoded by the MAGI1 gene.

<span class="mw-page-title-main">Angiomotin-like protein 1</span> Protein-coding gene in the species Homo sapiens

Angiomotin-like protein 1 is a protein that in humans is encoded by the AMOTL1 gene.

<span class="mw-page-title-main">AMOTL2</span> Protein-coding gene in the species Homo sapiens

Angiomotin-like protein 2 is a protein that in humans is encoded by the AMOTL2 gene.

<span class="mw-page-title-main">WWTR1</span> Protein-coding gene in the species Homo sapiens

WW domain-containing transcription regulator protein 1 (WWTR1), also known as Transcriptional coactivator with PDZ-binding motif (TAZ), is a protein that in humans is encoded by the WWTR1 gene. WWTR1 acts as a transcriptional coregulator and has no effect on transcription alone. When in complex with transcription factor binding partners, WWTR1 helps promote gene expression in pathways associated with development, cell growth and survival, and inhibiting apoptosis. Aberrant WWTR1 function has been implicated for its role in driving cancers. WWTR1 is often referred to as TAZ due to its initial characterization with the name TAZ. However, WWTR1 (TAZ) is not to be confused with the protein tafazzin, which originally held the official gene symbol TAZ, and is now TAFAZZIN.

The Akt signaling pathway or PI3K-Akt signaling pathway is a signal transduction pathway that promotes survival and growth in response to extracellular signals. Key proteins involved are PI3K and Akt.

<span class="mw-page-title-main">Dishevelled</span> Family of proteins

Dishevelled (Dsh) is a family of proteins involved in canonical and non-canonical Wnt signalling pathways. Dsh is a cytoplasmic phosphoprotein that acts directly downstream of frizzled receptors. It takes its name from its initial discovery in flies, where a mutation in the dishevelled gene was observed to cause improper orientation of body and wing hairs. There are vertebrate homologs in zebrafish, Xenopus (Xdsh), mice and humans. Dsh relays complex Wnt signals in tissues and cells, in normal and abnormal contexts. It is thought to interact with the SPATS1 protein when regulating the Wnt Signalling pathway.

<span class="mw-page-title-main">Rho-associated protein kinase</span>

Rho-associated protein kinase (ROCK) is a kinase belonging to the AGC family of serine-threonine specific protein kinases. It is involved mainly in regulating the shape and movement of cells by acting on the cytoskeleton.

<span class="mw-page-title-main">IMD domain</span>

In molecular biology, the IMD domain is a BAR-like domain of approximately 250 amino acids found at the N-terminus in the insulin receptor tyrosine kinase substrate p53 (IRSp53/BAIAP2) and in the evolutionarily related IRSp53/MIM (MTSS1) family. In IRSp53, a ubiquitous regulator of the actin cytoskeleton, the IMD domain acts as conserved F-actin bundling domain involved in filopodium formation. Filopodium-inducing IMD activity is regulated by Cdc42 and Rac1 and is SH3-independent. The IRSp53/MIM family is a novel F-actin bundling protein family that includes invertebrate relatives:

Tight junction proteins are molecules situated at the tight junctions of epithelial, endothelial and myelinated cells. This multiprotein junctional complex has a regulatory function in passage of ions, water and solutes through the paracellular pathway. It can also coordinate the motion of lipids and proteins between the apical and basolateral surfaces of the plasma membrane. Thereby tight junction conducts signaling molecules, that influence the differentiation, proliferation and polarity of cells. So tight junction plays a key role in maintenance of osmotic balance and trans-cellular transport of tissue specific molecules. Nowadays is known more than 40 different proteins, that are involved in these selective TJ channels.

References

  1. 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000041688 - Ensembl, May 2017
  2. "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  3. "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
  4. 1 2 3 Troyanovsky B, Levchenko T, Månsson G, Matvijenko O, Holmgren L (March 2001). "Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation". The Journal of Cell Biology. 152 (6): 1247–54. doi:10.1083/jcb.152.6.1247. PMC   2199208 . PMID   11257124.
  5. 1 2 3 Bratt A, Birot O, Sinha I, Veitonmäki N, Aase K, Ernkvist M, Holmgren L (October 2005). "Angiomotin regulates endothelial cell-cell junctions and cell motility". The Journal of Biological Chemistry. 280 (41): 34859–69. doi: 10.1074/jbc.M503915200 . PMID   16043488.
  6. 1 2 Bratt A, Wilson WJ, Troyanovsky B, Aase K, Kessler R, Van Meir EG, Holmgren L, Meir EG (September 2002). "Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains". Gene. 298 (1): 69–77. doi:10.1016/S0378-1119(02)00928-9. PMID   12406577.
  7. "Entrez Gene: AMOT angiomotin".
  8. 1 2 Zetter BR (March 2001). "Hold that line. Angiomotin regulates endothelial cell motility". The Journal of Cell Biology. 152 (6): F35-6. doi:10.1083/jcb.152.6.F35. PMC   2199203 . PMID   11257132.
  9. "RCSB PDB - Gene View - AMOT - angiomotin". RCSB Protein Data Bank.
  10. 1 2 3 Ernkvist M, Aase K, Ukomadu C, Wohlschlegel J, Blackman R, Veitonmäki N, Bratt A, Dutta A, Holmgren L (May 2006). "p130-angiomotin associates to actin and controls endothelial cell shape". The FEBS Journal. 273 (9): 2000–11. doi: 10.1111/j.1742-4658.2006.05216.x . PMID   16640563.
  11. "AMOT - Angiomotin - Homo sapiens (Human) - AMOT gene & protein". www.uniprot.org. Retrieved 2016-10-16.
  12. 1 2 Levchenko T, Aase K, Troyanovsky B, Bratt A, Holmgren L (September 2003). "Loss of responsiveness to chemotactic factors by deletion of the C-terminal protein interaction site of angiomotin". Journal of Cell Science. 116 (Pt 18): 3803–10. doi:10.1242/jcs.00694. PMID   12902404. S2CID   790463.
  13. Levchenko T, Bratt A, Arbiser JL, Holmgren L (February 2004). "Angiomotin expression promotes hemangioendothelioma invasion". Oncogene. 23 (7): 1469–73. doi:10.1038/sj.onc.1207264. PMID   14730344. S2CID   2244925.
  14. 1 2 Ernkvist M, Birot O, Sinha I, Veitonmaki N, Nyström S, Aase K, Holmgren L (March 2008). "Differential roles of p80- and p130-angiomotin in the switch between migration and stabilization of endothelial cells". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1783 (3): 429–37. doi:10.1016/j.bbamcr.2007.11.018. hdl: 10616/39669 . PMID   18164266.
  15. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, Guan KL (January 2011). "Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein". Genes & Development. 25 (1): 51–63. doi:10.1101/gad.2000111. PMC   3012936 . PMID   21205866.
  16. Paramasivam M, Sarkeshik A, Yates JR, Fernandes MJ, McCollum D (October 2011). "Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor". Molecular Biology of the Cell. 22 (19): 3725–33. doi:10.1091/mbc.E11-04-0300. PMC   3183025 . PMID   21832154.
  17. Chan SW, Lim CJ, Chong YF, Pobbati AV, Huang C, Hong W (March 2011). "Hippo pathway-independent restriction of TAZ and YAP by angiomotin". The Journal of Biological Chemistry. 286 (9): 7018–26. doi: 10.1074/jbc.C110.212621 . PMC   3044958 . PMID   21224387.
  18. Hirate Y, Hirahara S, Inoue K, Suzuki A, Alarcon VB, Akimoto K, Hirai T, Hara T, Adachi M, Chida K, Ohno S, Marikawa Y, Nakao K, Shimono A, Sasaki H (July 2013). "Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos". Current Biology. 23 (13): 1181–94. doi:10.1016/j.cub.2013.05.014. PMC   3742369 . PMID   23791731.
  19. Dai X, She P, Chi F, Feng Y, Liu H, Jin D, Zhao Y, Guo X, Jiang D, Guan KL, Zhong TP, Zhao B (November 2013). "Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis". The Journal of Biological Chemistry. 288 (47): 34041–51. doi: 10.1074/jbc.M113.518019 . PMC   3837143 . PMID   24106267.
  20. Hirate Y, Sasaki H (January 2014). "The role of angiomotin phosphorylation in the Hippo pathway during preimplantation mouse development". Tissue Barriers. 2 (1): e28127. doi:10.4161/tisb.28127. PMC   4022607 . PMID   24843842.
  21. Li Y, Zhou H, Li F, Chan SW, Lin Z, Wei Z, Yang Z, Guo F, Lim CJ, Xing W, Shen Y, Hong W, Long J, Zhang M (July 2015). "Angiomotin binding-induced activation of Merlin/NF2 in the Hippo pathway". Cell Research. 25 (7): 801–17. doi:10.1038/cr.2015.69. PMC   4493278 . PMID   26045165.
  22. Thanh Nguyen H, Andrejeva D, Gupta R, Choudhary C, Hong X, Eichhorn PJ, Loya AC, Cohen SM (2016-03-29). "Deubiquitylating enzyme USP9x regulates hippo pathway activity by controlling angiomotin protein turnover". Cell Discovery. 2: 16001. doi:10.1038/celldisc.2016.1. PMC   4849470 . PMID   27462448.
  23. Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmäki N, Levchenko T, Carlson LM, Musiani P, Iezzi M, Curcio C, Forni G, Cavallo F, Kiessling R (June 2006). "A DNA vaccine targeting angiomotin inhibits angiogenesis and suppresses tumor growth". Proceedings of the National Academy of Sciences of the United States of America. 103 (24): 9208–13. doi: 10.1073/pnas.0603110103 . PMC   1482591 . PMID   16754857.
  24. Jiang WG, Watkins G, Douglas-Jones A, Holmgren L, Mansel RE (2006-01-01). "Angiomotin and angiomotin like proteins, their expression and correlation with angiogenesis and clinical outcome in human breast cancer". BMC Cancer. 6: 16. doi: 10.1186/1471-2407-6-16 . PMC   1386688 . PMID   16430777.
  25. Lv M, Lv M, Chen L, Qin T, Zhang X, Liu P, Yang J (April 2015). "Angiomotin promotes breast cancer cell proliferation and invasion". Oncology Reports. 33 (4): 1938–46. doi: 10.3892/or.2015.3780 . PMID   25647626.
  26. Stalin J, Harhouri K, Hubert L, Subrini C, Lafitte D, Lissitzky JC, Elganfoud N, Robert S, Foucault-Bertaud A, Kaspi E, Sabatier F, Aurrand-Lions M, Bardin N, Holmgren L, Dignat-George F, Blot-Chabaud M (March 2013). "Soluble melanoma cell adhesion molecule (sMCAM/sCD146) promotes angiogenic effects on endothelial progenitor cells through angiomotin". The Journal of Biological Chemistry. 288 (13): 8991–9000. doi: 10.1074/jbc.M112.446518 . PMC   3610971 . PMID   23389031.

Further reading